$17.3M
Qualified
maximum offering price, as qualified
—
Reported Sold
no 1-K or 1-Z states a sold amount
4
Filings
across 1 offering
Equity Classes
| Type | Class | Outstanding |
|---|---|---|
| common | Common Equity | 10,536,004 |
| debt | Convertible notes payable | 386,825 |
Service Providers
| Role | Provider |
|---|---|
| auditor | GBH CPAs, PC |
| legal | Schiff Hardin LLP |
| underwriter | Boustead Securities, LLC |
Offerings
| File Number | Filings | First Filed | Last Filed | Price/Security | Securities Offered | Outstanding | Aggregate Offering | Estimated Net | Withdrawn |
|---|---|---|---|---|---|---|---|---|---|
| 024-10855 | 4 | 2018-06-15 | 2018-10-26 | $6.00 | 2,875,000 | 10,536,004 | $17.3M | $15.7M | 2019-03-28 |
The statements and reported figures behind CNS Pharmaceuticals, Inc.
Operations, the balance sheet and cash flows as filed, year by year — the filer's own captions, not a mapped chart of accounts — plus the tagged figures from every Form 1-A family filing, plotted on the dates they were actually reported. EDGAR still has each 1-K; the dashboard lays every year they filed next to it.
- Every caption as the filer wrote it, across every annual report — not just the latest 1-K
- Tagged reported figures across every filing — revenue, assets, cash — with a sparkline on the actual filing dates
- A sparkline on each annual-statement line, so the shape is visible before the figures
- A revenue series dated to the filings that reported it
- A filing history that says what each document contributed, not only that it exists
- Follow it, and see it change on your watchlist
External link: SEC Filings